



(51) International Patent Classification:
A61K 31/535 (2006.01)

(21) International Application Number:
PCT/US2015/050289

(22) International Filing Date:
15 September 2015 (15.09.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/051,268 16 September 2014 (16.09.2014) US

(71) Applicant: **QUANTICEL PHARMACEUTICALS, INC.** [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, California 92121 (US).

(72) Inventors: **CHEN, Young K.**; 746 Santa Barbara Drive, San Marcos, California 92078 (US). **NIE, Zhe**; 17104 Monterey Ridge Way, San Diego, California 92127 (US). **STAFFORD, Jeffrey Alan**; 12752 Sandy Crest Court, San Diego, California 92130 (US). **VEAL, James Marvin**; 8916 Weaver Crossing Road, Apex, North Carolina 27502 (US).

(74) Agent: **CLARK, David L.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: HISTONE DEMETHYLASE INHIBITORS

(57) Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as pancreatic cancer, prostate cancer, breast cancer, bladder cancer, lung cancer, gastric cancer, leukemia and/or melanoma and the like.



PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

To:

SUNG, Lawrence M.
Wiley Rein LLP
Patent Administration
1776 K Street, NW
Washington, DC 20006
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 09 March 2017 (09.03.2017)	
Applicant's or agent's file reference 873860018PCT	IMPORTANT NOTIFICATION
International application No. PCT/US2015/050289	International filing date (day/month/year) 15 September 2015 (15.09.2015)

1. The following indications appeared on record concerning: ☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative		
Name and Address QUANTICEL PHARMACEUTICALS, INC. 9393 Towne Centre Drive Suite 110 San Diego, California 92121 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence		
Name and Address CELGENE QUANTICEL RESEARCH, INC. 9393 Towne Centre Drive Suite 110 San Diego, California 92121 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to: ☒ the receiving Office ☐ the International Searching Authority ☐ the Authority(ies) specified for supplementary search ☐ the International Preliminary Examining Authority ☒ the designated Offices concerned ☐ the elected Offices concerned ☐ other:		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 89 95	Authorized officer Safi Horiya e-mail pct.team4@wipo.int Telephone No. +41 22 338 74 04
--	---